Rheumatic fever secondary prevention
|
Rheumatic fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rheumatic fever secondary prevention On the Web |
|
American Roentgen Ray Society Images of Rheumatic fever secondary prevention |
|
Risk calculators and risk factors for Rheumatic fever secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Lance Christiansen, D.O.; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]
Secondary Prevention
If an individual does not contract a Streptococcus pyogenes infection for a long period, perhaps for five years or longer, an individual's immunological/autoimmunological responsivness will naturally decrease and, perhaps, there will be less chance of developing rheumatic fever if the individual contracts a future Streptococcus pyogenes infection.
Providing prophylactic therapy to individuals who have had rheumatic fever with monthly (or maybe every three weeks) injections of Benzathine Penicillin G, 1,200,000 units, or oral penicillin V or G, 250mg twice daily (I think 500 mg twice daily is more efficacious), decreases the frequency of recurrent Streptococcus pyogenes infections and therefore recurrent rheumatic fever episodes. It is estimated that the recurrence rate of rheumatic fever is decreased about 85% by providing prophylactic penicillin therapy.
| Agent | Dosage | Mode |
|---|---|---|
| Benzathine penicillin G | 1,200,000 Units every 4 weeks (every 3 weeks for high-risk patients such as those with residual carditis) | Intramuscular |
| or | ||
| Penicillin V | 250 mg twice daily | Oral |
| or | ||
| Sulfadiazine | 0.5 g once daily for patients ≤ 27 kg (60 lb); 1.0 g once daily for patients > 27 kg (60 lb) | Oral |
| or | ||
| Erythromycin among patients with penicillin allergy | 250 mg twice daily | Oral |
Sources
2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.[1]
References
- ↑ 1.0 1.1 Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172.